Dietary supplements containing drugs recalled due to serious health risks
Umary USA announced a voluntary recall of dietary supplements marketed nationwide for joint pain and arthritis relief as they contain drugs that pose serious health risks, according to the U.S. Food and Drug Administration.
All lots and dates of the supplements, Unavy Ácido Hialurónico and Umovy Ácido Hialurónico caplets, are covered by the recall. Consumers who purchased the supplements should immediately stop taking them and consult their health care provider for safe discontinuation of use.
The caplets contain the undeclared drugs diclofenac, dexamethasone and omeprazole, according to the FDA. Because they contain those drugs, they cannot be marketed as dietary supplements. Their safety and effectiveness have not been established, according to the FDA.
'Dexamethasone, a corticosteroid, can weaken the immune system, cause high blood sugar, muscle damage, psychiatric effects and cardiovascular problems,' the FDA press release states. 'Prolonged or high-dose use may suppress adrenal gland function and abrupt stopping can lead to withdrawal symptoms.'
'Diclofenac, a non-steroidal anti-inflammatory drug (NSAID), may cause severe cardiovascular, gastrointestinal, kidney, and allergic reactions, especially in patients taking other NSAIDs or blood thinners or those with allergies or underlying health issues,' the statement reads.
'Omeprazole, a proton pump inhibitor used to treat stomach acid disorders, might mask serious gastric conditions such as ulcers or cancer if taken unknowingly,' the statement reads.
Unavy Ácido Hialurónico comes in a white plastic bottle with a black label marked with white and yellow text. Umovy Ácido Hialurónico is packaged in a black plastic bottle with a black label featuring white and blue lettering. Both products come in 30-count, 850-mg caplets.
The supplements were distributed nationwide by Umary USA, which is notifying distributors and customers by press release and email. The company is arranging for returns and refunds, according to the FDA.
There have been no reported adverse reactions linked to using the two products. Consumers who are experiencing problems related to the caplets should contact their healthcare provider and report issues to the FDA's MedWatch program online.
For questions about the recall, consumers can contact Umary USA at umaryusa2025@gmail.com, available 24/7.
For more information, visit the official FDA recall notice here.
Multi-state salmonella outbreak linked to recalled cucumbers
Public health alert: Listeria found in Big Y, Price Chopper ready-to-eat wrap
Tattoo ink recalled due to contamination with infection-causing microorganisms
Read the original article on MassLive.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
an hour ago
- Fox News
Cannabis
Cannabis is a drug that comes from the dried leaves, flowers, stems, and seeds of a cannabis sativa plant. Cannabis is commonly referred to as weed or marijuana, though marijuana refers to a specific part of the cannabis plant that contains high amounts of the psychoactive compound THC (tetrahydrocannabinol), which has mind-altering effects. CBD (cannabidiol) is another compound found in cannabis. In a single year, 52.5 million people in the United States use cannabis at least once, according to 2021 data from the Centers for Disease Control and Prevention (CDC). Cannabis has a direct effect on the brain, specifically the parts used for learning, decision-making, emotion, memory, reaction time, coordination, and attention, the CDC states. Marijuana is commonly smoked for recreational purposes. There are few prescription cannabis drugs approved by the Food and Drug Administration (FDA) for medicinal purposes. One example is Epidiolex, which is used to treat seizures. The legalization of marijuana is a varying issue on a state-by-state basis. Some states have legalized marijuana for medicinal purposes, while in others marijuana is legal for both recreational and medicinal purposes. Idaho, Kansas, South Carolina and Wyoming are the only states where marijuana is fully illegal.
Yahoo
an hour ago
- Yahoo
Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints
Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated statistically significant and clinically meaningful improvement compared to placebo in all primary, key secondary, and secondary endpoints Denifanstat demonstrated a favorable safety and tolerability profile Denifanstat was 98% and 178% more effective than U.S. Food and Drug Administration (FDA)-approved sarecycline and doxycycline with regard to placebo-adjusted percent treatment success, respectively, 18.6% for denifanstat versus 9.4% for sarecycline, 18.6% versus 6.7% for doxycycline Denifanstat was 60% more effective than FDA-approved clascoterone cream with regard to placebo-adjusted percent treatment success, 18.6% for denifanstat versus 11.6% for clascoterone cream, respectively The exceptional efficacy of denifanstat coupled with its favorable safety profile in the Phase III trial provides a potential major break-through for the treatment of acne HONG KONG, June 3, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that denifanstat (ASC40), a first-in-class, once-daily oral small molecule fatty acid synthase (FASN) inhibitor, meets all primary, key secondary, and secondary endpoints in the Phase III clinical trial for the treatment of moderate to severe acne vulgaris (NCT06192264). The Phase III clinical trial was a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of denifanstat once-daily oral tablet in 480 patients with moderate to severe acne vulgaris. Patients were enrolled and randomized into one active treatment arm and one placebo control arm at the ratio of 1:1 to receive 50 mg denifanstat oral tablet once daily or matching placebo for 12 weeks. Baseline characteristics were well balanced between denifanstat and placebo arms. Table 1 summarizes some of baseline characteristics. Primary, key secondary, and secondary endpoints can be found in Table 2. Primary endpoints included the percent treatment success (defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease in IGA from baseline at week 12), the percent reduction from baseline in total lesion count, and the percent reduction from baseline in inflammatory lesion count. At week 12, percent treatment success was 33.2% compared to 14.6% for placebo, p<0.0001, percent reduction from baseline in total lesion count was 57.4% compared to 35.4% for placebo, p<0.0001, and percent reduction from baseline in inflammatory lesion count was 63.5% compared to 43.2% for placebo, p<0.0001. The key secondary endpoint, percent reduction from baseline in non-inflammatory lesion count at week 12, was 51.9% compared to 28.9% for placebo, p<0.0001. Denifanstat demonstrated a favorable safety and tolerability profile following 12 weeks of once-daily oral administration at 50 mg. The incidence rates of treatment-emergent adverse events (TEAEs) were comparable between denifanstat and placebo. No incidence rates of TEAEs related to study drug in any category exceeded 10%. Only two categories of TEAEs had an incidence rate of more than 5% (6.3% dry skin in denifanstat-treated patients versus 2.9% in the placebo group; 5.9% dry eye in denifanstat-treated patients versus 3.8% in the placebo group). All denifanstat-related adverse events (AEs) were mild or moderate. There were no denifanstat-related grade 3 or 4 AEs and no denifanstat-related serious AEs (SAEs). No deaths were reported. The mechanisms of action of denifanstat for the treatment of acne are (1) direct inhibition of facial sebum production, through inhibition of de novo lipogenesis (DNL) in human sebocytes; and (2) inhibition of inflammation, through decreasing cytokine secretion and Th17 differentiation. Denifanstat's unique mechanism of action directly reduces one of the main underlying causes of acne which is the overproduction of sebum. This makes denifanstat unique as most other acne treatments do not treat the underlying cause of the condition. "We are extremely pleased with the topline results of our Phase III trial. Denifanstat tablets demonstrated impressive efficacy beyond treatment success, showing significant reductions in total lesion count, inflammatory lesion count, and non-inflammatory lesion count. We are excited to be submitting this innovative treatment with the China National Medical Products Administration (NMPA) soon." said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. Table 3 highlights the excellent efficacy of denifanstat in a non-head-to-head comparison to other commonly used oral and topical acne treatments. Denifanstat demonstrated its exceptional efficacy across multiple key metrics compared to sarecycline, doxycycline and clascoterone cream. With regard to the placebo-adjusted percent treatment success and the placebo-adjusted percent reduction from baseline in inflammatory lesion count, denifanstat was 98% and 30% more effective than sarecycline, respectively, 178% and 178% more effective than doxycycline, respectively, and 60% and 59% more effective than clascoterone cream, respectively. With regard to the placebo-adjusted percent reduction from baseline in total lesion count, denifanstat was 189% and 85% more effective than doxycycline and clascoterone cream, respectively. With regard to the placebo-adjusted percent reduction from baseline in non-inflammatory lesion count, denifanstat was 411% and 102% more effective than sarecycline and clascoterone cream, respectively. Denifanstat has the potential to be a first-in-class, once-daily, oral acne therapeutic, potentially offering both exceptional efficacy and patient compliance with a favorable safety and tolerability profile. Compared to other oral acne treatments, denifanstat provides outstanding efficacy with excellent safety. There is no potential for antibiotic resistance or off target effects which can occur with tetracycline derivatives and no reported denifanstat-related severe AEs such as hepatotoxicity, hearing impairment and depression which are seen with isotretinoin. Denifanstat should also provide better adherence to treatment compared to topical therapies: an estimated 30% to 40% of patients do not adhere to their topical treatments[1]. Denifanstat is licensed from Sagimet Biosciences Inc. (Nasdaq: SGMT) for exclusive rights in Greater China. "The Phase III clinical trial results for denifanstat are highly encouraging. The data demonstrate statistically significant improvements in treatment outcomes for moderate-to-severe acne patients, with percent treatment success of 33.2%, total lesion count reduction of 57.4% from baseline, inflammatory and non-inflammatory lesion counts decreasing by 63.5% and 51.9%, respectively, while maintaining a favorable safety and tolerability profile. Denifanstat's first-in-class mechanism targeting FASN directly addresses a key cause for acne, establishing it as a groundbreaking therapeutic approach in acne treatment." said Prof. Leihong Xiang, Chief Physician of Dermatological Department, Huashan Hospital, Fudan University, Executive Deputy Director of Institute of Dermatology, Fudan University, Deputy Director of Dermatology Division of Chinese Medical Doctor Association and principal investigator of denifanstat Phase III trial for moderate to severe acne. [1] Purvis CG, Balogh EA, Feldman SR. Clascoterone: How the Novel Androgen Receptor Inhibitor Fits Into the Acne Treatment Paradigm. Ann Pharmacother. 2021;55(10):1297-1299. doi:10.1177/1060028021992055. Table 1. Baseline characteristics of Phase III trial of denifanstat Baseline characteristics 50 mg denifanstat, oral, oncedaily (n=240) Placebo, oral, once daily (n=240) Total lesion count 102.2 102.1 Inflammatory lesion count 42.1 43.1 IGA=3 (moderate), % 85.8 85.8 IGA=4 (severe), % 14.2 14.2 Table 2. Efficacy endpoints of 50 mg denifanstat oral, once daily at week 12 versus placebo (intent-to-treat, ITT, analysis) Efficacy endpoints (1) 50 mg denifanstat, oral, once daily (n=240) Placebo, oral,once daily (n=240) Placebo adjusted p value Percent treatment success (2) (primary endpoint) 33.2 14.6 18.6 <0.0001 Percent reduction from baseline in total lesion count (primary endpoint) 57.4 35.4 22.0 <0.0001 Percent reduction from baseline ininflammatory lesion count (primary endpoint) 63.5 43.2 20.3 <0.0001 Percent reduction from baseline in non-inflammatory lesion count (key secondary endpoint) 51.9 28.9 23.0 <0.0001 Absolute reduction from baseline intotal lesion count (secondary endpoint) 58.3 36.2 22.1 <0.0001 Absolute reduction from baseline in inflammatory lesion count (secondaryendpoint) 26.6 18.4 8.2 <0.0001 Notes: (1) All efficacy endpoints are least square means.(2) Treatment success is defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease in IGA from baseline at week 12. Table 3. Denifanstat compared to other commonly used acne treatments (not head-to-head comparison) Category Denifanstat (n=240) Sarecycline(1) (n=1002) Doxycycline(2) (n=216) Clascoterone cream(3) (n=722) Baseline characteristics Total lesion count 102.2 72.4 71.7 103.6 Inflammatory lesion count 42.1 30.0 33.6 42.7 IGA=3 (moderate), % 85.8 85.2 93.5 82.7 IGA=4 (severe), % 14.2 14.9 6.5 17.3 Efficacy endpoints at week 12 Placebo-adjusted percenttreatment success 18.6 9.4 6.7 11.6 Placebo-adjusted percent reductionfrom baseline in total lesion count 22.0 NA 7.6 11.9 Placebo-adjusted percent reductionfrom baseline in inflammatorylesion count 20.3 15.6 7.3 12.8 Placebo-adjusted percent reduction from baseline in non-inflammatorylesion count 23.0 4.5 NA 11.4 Notes: (1) The sarecycline data represent an analysis of its two Phase III clinical trials, with values expressed as means. The data are from Moore, A., et al., J Drugs Dermatol 2018 Vol. 17 Issue 9 Pages 987-996. The non- inflammatory lesion count data are from FDA ( The doxycycline data at week 16 are from Moore, A., et al., J Drugs Dermatol 2015 Vol. 14 Issue 6 Pages 581-6.(3) The clascoterone cream (1%) data represent an analysis of its two Phase III clinical trials, with values expressed as means. The data are from Hebert. A, et al., JAMA Dermatology 2020 Vol. 156 Issue 6, DOI: 10.1001/jamadermatol.2020.0465. About Ascletis Pharma Inc. Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange ( covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on metabolic diseases by addressing unmet medical needs from a global perspective. Ascletis has multiple clinical stage drug candidates in its metabolic disease pipeline. For more information, please visit Contact: Peter VozzoICR Healthcare443-231-0505 (U.S.) Ascletis Pharma Inc. PR and IR teams+86-181-0650-9129 (China)pr@ ir@ View original content: SOURCE Ascletis Pharma Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
The FDA Just Upgraded a Recall On This Popular Breakfast Item To The Highest Level—Here's What to Know
The FDA Just Upgraded a Recall On This Popular Breakfast Item To The Highest Level—Here's What to Know originally appeared on Parade. You'd be surprised just how contentious a conversation about bagels can get. Sure, they might seem innocuous and like a relatively safe topic of discussion, but if you get the right people in the room, things can go south pretty quickly. Born and raised New Yorkers know a thing or two about where to get the best bagels and you better not even think about scooping out the insides like they do in LA. There are even rules about slicing, and according to some people the water in Jersey makes their bagels the best on the planet. Told you it was a minefield. 😋😋SIGN UP to get delicious recipes, handy kitchen hacks & more in our daily Pop Kitchen newsletter🍳🍔 Regardless of how you like your bagel—toasted, schmeared with cream cheese, buttered, or topped with lox—there's no denying that it's one of the greatest grab-and-go breakfasts known to mankind. It's filling and satiating leaving and can easily go from sweet to savory without skipping a beat. No matter what side of the bagel spectrum you fall on, we can all agree, life's sweeter with one in only thing that could possibly make us put the carby wonders down for good is if, by some chance, the unassuming doughy breakfast companion turned out to be hazardous to our health and the health of those around us. Unfortunately, in the case of Utah-based bagel company New Grains Gluten Free Bakery, it looks like that just might be the case. According to a recent filing by the FDA, the recall was issued due to the undeclared presence of eggs in four varieties of gluten-free bagels—cinnamon raisin, plain, blueberry, and multigrain. Approximately 100 units of each type were affected by the recall. The recall is listed as Class I, the highest threat level, due to the potential for serious and life-threatening allergic reactions if consumed by someone with an egg allergy. In addition to the bagels, the brand also included artisan white bread, multigrain bread, sourdough, and cinnamon raisin bread in the recall due to the same labeling issue. The products were distributed between April 4 and 21 under lot numbers 90-107 and were packaged in clear, vacuum-sealed plastic bags. A total of 250 units of each product were distributed to retail locations in Utah, so it seems that the recall is relatively insulated for now. While there have been no reported injuries or illnesses, it's best to avoid consumption if you happen to have purchased one of the affected products. Of course, yours truly isn't allergic to eggs, so I'll make sure to eat one for the both of us FDA Just Upgraded a Recall On This Popular Breakfast Item To The Highest Level—Here's What to Know first appeared on Parade on Jun 3, 2025 This story was originally reported by Parade on Jun 3, 2025, where it first appeared.
